This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • HIV/AIDS  • Drug Therapy  • Drug Therapy, Other  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Rachael Jones, MD, MRCP; Mark Nelson, MD, FRCP; Mark Bower, PhD, FRCP, FRCPath; Tom Powles, MD, MRCP; Sundhiya Mandalia, PhD; Brian Gazzard, MD, FRCP; Justin Stebbing, PhD, MRCP, MRCPath

Arch Intern Med. 2008;168(17):1926-1927.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Triple-class resistance constitutes a major treatment challenge in the era of highly active antiretroviral therapy (HAART).^1-3 It is found in antiretroviral naïve individuals due to transmission of drug-resistant strains, although the majority of cases have extensive prior antiretroviral exposure.⁴ Despite the increasing use of potent combinations, inadequate suppression of viremia is likely to be associated with risks of acquiring further resistant mutations and an increased risk of disease progression and mortality.⁵ In the recently published update of the UK Collaborative HIV (UK CHIC) study, it was shown that extensive virologic failure to the 3 main antiretroviral classes occurred in 9.2% of individuals over 10 years in routine clinical practice.⁶ To investigate this further, our objective was to establish the prevalence, risk . . . [Full Text of this Article]

Methods


Results

Comment

AUTHOR INFORMATION


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?